Products and New Molecular Entities
Boehringer Ingelheim has brought a range of successful products from own drug discovery to market. A number of these drugs have either achieved blockbuster status with annual sales exceeding one billion US Dollar or have blockbuster potential. Continuously, our improvement initiatives have increased our research productivity and have resulted in a well-balanced pipeline showing a substantial number of new molecular entities and a high share of products in late phase development.
Successful Products from our own Research & Development
| Product name
|
First launch
|
Active ingredient
|
Indication
|
|---|---|---|---|
| Pradaxa®
|
2010
2008
|
dabigatran etexilate
|
Stroke Prevention in atrial fibrillation
Prevention of venous thromboembolic events (VTE) in adults
|
|
Spiriva®
Respimat Soft Mist™ Inhaler
Spiriva®
|
2007
2002
|
tiotropium |
COPD |
| Micardis® | 1998 | telmisartan | Essential hypertension |
|
Sifrol® / Mirapex® / Mirapexin® |
2006
1997 |
pramipexole |
Restless legs syndrome (RLS)
|
| Viramune® | 1996 | nevirapine | HIV/AIDS |
Promising Compounds in our Pipeline - Examples
| Clinical phase | Compound*
|
Indication
|
Therapeutic principle
|
Mode of action
|
|---|---|---|---|---|
| Phase III | Dabigatran etexilate (Pradaxa®) |
Acute venous thrombo-embolism (VTE)/ Secondary VTE |
Anticoagulation | Oral direct inhibition of Thrombin |
| Phase III | Linagliptin |
Diabetes mellitus
|
DPP-IV antagonist
|
Dipeptidylpeptidase-IV inhibitor
|
| Phase III | BI 10773 | Diabetes mellitus type II | SGLT-2-antagonist | Inhibition of glucose transporter-2
|
| Phase III | BI 201335 | Hepatitis C | Direct virus targeting small molecule | Oral HCV NS3/4A protease |
| Phase III | BIBF 1120 (Vargatef
TM **)
|
Non-small cell
lung cancer (NSCLC) |
Angiogenesis inhibition
|
Triple angiokinase inhibitor simultaneously blocks VEGFR, FGFR, PDGFR
|
| Phase III |
BIBF 1120
|
Ovarian cancer
|
Angiogenesis inhibition | Triple angiokinase inhibitor simultaneously blocks VEGFR, FGFR, PDGFR |
| Phase III | Afatinib | Non-small cell
lung cancer (NSCLC) |
Signal transduction inhibition
|
Dual
irreversible EGFR/HER2 inhibitor
|
| Phase III | Afatinib | Breast cancer | Signal transduction inhibition | Dual irreversible EGFR/HER2 inhibitor |
| Phase III | BIBF 1120 | Idiopathic Pulmonary Fibrosis (IPF) | Anti-fibrotic kinase inhibition | Anti-fibrotic kinase inhibitor |
| Phase II | BI 207127 | Hepatitis C | Direct virus targeting small molecule | Oral NS5B RNA-dependent |
| Phase II | Volasertib
|
Variety of cancer types |
Cell-cycle kinase inhibition | PLK-1 antagonist |
| Phase I | New compound
|
Variety of
cancer types |
Cell-cycle kinase inhibition |
Mitotic checkpoint inhibitor |
| Phase I | New compound | Diabetes mellitus type II
|
11ß-HSD-1-antagonist
|
* These are investigational agents; their safety and efficacy have not yet been established.
** Planned Brand Name.
Status: April 2011
